Loading...
Recent guidelines have recommended expanded use of statins for primary prevention of adverse cardiovascular (CV) events based on estimated CV risk, but statin use for primary prevention often is constrained by concerns about possible adverse effects. Most systematic reviews have focused on secondary prevention trials; reviews of harms in primary prevention have been confounded by inconsistent definitions of muscle problems.
Researchers conducted a meta-analysis of 62 randomized trials in which statins were compared with nonstatin controls or with other types or doses of statins in 120,000 patients without known CV disease. During a mean follow-up of 3.9 years, statins were associated with small but significant increases in self-reported musc…